Is Trident Lifeline overvalued or undervalued?

As of 28 October 2025, the valuation grade for Trident Lifeline has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued in the current market context. Key ratios include a PE Ratio of 21.00, an EV to EBITDA of 17.76, and a PEG Ratio of 0.25, which suggests that while growth expectations are low, the current price does not adequately reflect the company's earnings potential.
In comparison to its peers, Trident Lifeline's PE Ratio is significantly lower than Sun Pharma's 35.35 and Divi's Lab's 74.05, both of which are categorized as very expensive. Conversely, Dr. Reddy's Labs and Cipla, which are rated attractive, have PE Ratios of 18.66 and 23.52, respectively, indicating that Trident Lifeline's valuation is not justified when looking at the broader industry landscape. Despite a strong 3-year return of 97.65%, the recent stock performance has lagged behind the Sensex, with a 1-year return of -2.32% compared to the Sensex's 5.78%.